lunes, 6 de mayo de 2013

Prediction of BRCA1 Germ-Line Mutation Status i... [Pathobiology. 2013] - PubMed - NCBI

Prediction of BRCA1 Germ-Line Mutation Status i... [Pathobiology. 2013] - PubMed - NCBI

Pathobiology. 2013 Apr 23;80(5):219-227. [Epub ahead of print]

Prediction of BRCA1 Germ-Line Mutation Status in Patients with Breast Cancer Using Histoprognosis Grade, MS110, Lys27H3, Vimentin, and KI67.


Department of Cancer Genetics/CIC-P Inserm 9502, Paoli Calmettes Institute, University of Aix-Marseille II, Marseille, France.


Family structure, lack of reliable information, cost, and delay are usual concerns when deciding to perform BRCA analyses. Testing breast cancer tissues with four antibodies (MS110, lys27H3, vimentin, and KI67) in addition to grade evaluation enabled us to rapidly select patients for genetic testing identification. We constituted an initial breast cancer tissue microarray, considered as a learning set, comprising 27 BRCA1 and 81 sporadic tumors. A second independent validation set of 28 BRCA1 tumors was matched to 28 sporadic tumors using the same original conditions. We investigated morphological parameters and 21 markers by immunohistochemistry. A logistic regression model was used to select the minimal number of markers providing the best model to predict BRCA1 status. The model was applied to the validation set to estimate specificity and sensibility. In the initial set, univariate analyses identified 11 markers significantly associated with BRCA1 status. Then, the best multivariate model comprised only grade 3, MS110, Lys27H3, vimentin, and KI67. When applied to the validation set, BRCA1 tumors were correctly classified with a sensitivity of 83% and a specificity of 81%. The performance of this model was superior when compared to other profiles. This study offers a new rapid and cost-effective method for the prescreening of patients at high risk of being BRCA1 mutation carriers, to guide genetic testing, and finally to provide appropriate preventive measures, advice, and treatments including targeted therapy to patients and their families.
Copyright © 2013 S. Karger AG, Basel.
[PubMed - as supplied by publisher]

No hay comentarios:

Publicar un comentario